Business Description
Virax Biolabs Group Ltd
Description
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 64.06 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -65 | |||||
| 3-Year EPS without NRI Growth Rate | -101.9 | |||||
| 3-Year FCF Growth Rate | -45.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.88 | |||||
| 9-Day RSI | 42.89 | |||||
| 14-Day RSI | 44.52 | |||||
| 6-1 Month Momentum % | -51.2 | |||||
| 12-1 Month Momentum % | -88.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.61 | |||||
| Quick Ratio | 10.61 | |||||
| Cash Ratio | 10.3 | |||||
| Days Inventory | 766.5 | |||||
| Days Payable | 17434.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11 | |||||
| Shareholder Yield % | -1.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -11.11 | |||||
| Operating Margin % | -63700 | |||||
| Net Margin % | -60644.44 | |||||
| ROE % | -130.53 | |||||
| ROA % | -108.01 | |||||
| ROIC % | -986.75 | |||||
| ROCE % | -137.61 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 179.6 | |||||
| PB Ratio | 0.61 | |||||
| Price-to-Tangible-Book | 0.61 | |||||
| EV-to-EBIT | 0.51 | |||||
| EV-to-EBITDA | 0.51 | |||||
| EV-to-Revenue | -307.33 | |||||
| EV-to-FCF | 0.66 | |||||
| Price-to-Net-Current-Asset-Value | 0.61 | |||||
| Price-to-Net-Cash | 0.63 | |||||
| Earnings Yield (Greenblatt) % | 196.08 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRAX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Virax Biolabs Group Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.009 | ||
| EPS (TTM) ($) | -0.638 | ||
| Beta | 0 | ||
| Volatility % | 74.54 | ||
| 14-Day RSI | 44.52 | ||
| 14-Day ATR ($) | 0.027598 | ||
| 20-Day SMA ($) | 0.360975 | ||
| 12-1 Month Momentum % | -88.87 | ||
| 52-Week Range ($) | 0.3156 - 3.37 | ||
| Shares Outstanding (Mil) | 17.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Virax Biolabs Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Virax Biolabs Group Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Virax Biolabs Group Ltd Frequently Asked Questions
What is Virax Biolabs Group Ltd(VRAX)'s stock price today?
The current price of VRAX is $0.35. The 52 week high of VRAX is $3.37 and 52 week low is $0.32.
When is next earnings date of Virax Biolabs Group Ltd(VRAX)?
The next earnings date of Virax Biolabs Group Ltd(VRAX) is .
Does Virax Biolabs Group Ltd(VRAX) pay dividends? If so, how much?
Virax Biolabs Group Ltd(VRAX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers